Long-term safety study of KarXT for Alzheimer's psychosis
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished one of the earlier KarXT studies (KAR-031, KAR-032, or CN012-0056).
- You need to understand the study and give your permission (or have a family member give permission for you).
- You must have a stable place to live, like your own home or an assisted-living facility.
- You cannot have serious medical conditions that would make the study unsafe for you.
- You cannot join if you are currently in another drug or device study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Hear when a new Psychosis Associated With Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.